1. (A) Anti-MOG antibodies measured ...
(A) Anti-MOG antibodies measured by cell-based assay at baseline. The dashed line represents the cut-off. Twelve of one hundred and seventy-four patients (1–12) were MOG-seropositive. (B) Longitudinal serum samples revealed persisting anti-MOG antibodies in six patients and newly occurring in two (13–14). (C) Five out of one hundred and seventy-four patients were neurofascin 186-seropositive at baseline. (D) Longitudinal serum samples revealed persisting anti-neurofascin 186 antibodies in three patients and newly occurring in one (6). (E–G) Brain MRI of a MOG seropositive patient (Patient 1 in Fig. 1A and B, marked with *). (E, F) Coronary T2 fluid-attenuated image (FLAIR); (G) Axial FLAIR. Lesions are marked with red arrows. GMCFI: geometric mean channel fluorescence intensity; MOG: myelin oligodendrocyte glycoprotein.
Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (
Rheumatology (Oxford), Volume 58, Issue 5, 27 September 2018, Pages 908–913,
The content of this slide may be subject to copyright: please see the slide notes for details.

2. This cross-sectional study included 174 patients with SLE ...
This cross-sectional study included 174 patients with SLE that were part of the Swiss SLE Cohort Study. Serum samples at study baseline were screened for antibodies against 12 different myelin/neuronal antigens using cell-based assays. Antibodies against myelin oligodendrocyte glycoprotein and neurofascin 186 were additionally measured in longitudinal samples (*) where available (n = 102 patients, n = 182 samples, 1–5 follow-up samples/patient). The last row summarizes the number of patients (absolute and percentage of total cohort) that harbour or develop the various antibodies over the disease course and at baseline (in parentheses). Ig: immunoglobulin.
Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (
Rheumatology (Oxford), Volume 58, Issue 5, 27 September 2018, Pages 908–913,
The content of this slide may be subject to copyright: please see the slide notes for details.